VerityRank
Agilent Technologies, Inc.
Brand & Manufacturer VerifiedUnited States

Agilent Technologies, Inc.

Agilent

Agilent Technologies, Inc. is a global leader in analytical and life sciences instrumentation, headquartered in Santa Clara, California. Spun off from Hewlett-Packard in 1999, Agilent designs and manufactures chromatography, mass spectrometry, spectroscopy, cell analysis, and molecular diagnostics systems that operate in more than 285,000 laboratories worldwide. In FY2025 the company generated US$6,948 million in revenue, up 6.7% year-over-year, with core Q4 growth of 7.2%, employing approximately 18,100 people.

Strengths:
• Laboratory franchise – industry-standard chromatography and mass spectrometry platforms with deep installed base and recurring consumables revenue
• Diagnostics expansion – the US$950 million Biocare Medical acquisition (2026) added 300+ IHC and FISH assays, strengthening oncology testing
• Financial resilience – 6.7% revenue growth with accelerating core demand demonstrates successful post-downturn recovery
• Global manufacturing – self-manufacturing model with facilities across the US, Europe and Asia ensures supply-chain control

Weaknesses:
• Pharma capex exposure – spending slowdowns in biopharma capital equipment, driven by tariffs and macro uncertainty, pressured early-2025 demand
• Currency volatility – global FX swings periodically compress reported revenue and margins
• Competition in China – domestic instrument makers are intensifying price competition in Agilent's second-largest market
Read More
United StatesFounded 1999~18,100US$7 BManufacturing and R&D… / 100
Listed onNYSEA
Last updated: 2026-11-20 15:59 ET·By VerityRank Research Team·Methodology

Listed market data

A · NYSE · weeklyHistory →
Market cap
$48.8 B
Share price
USD 170.38
1Y change
+22.0%
Recent change
-2.8%

11-19 → 11-20

IPO price
+467.9%

USD 30.00 · from 1999-11-18

Revenue (TTM)
$7.4 B
After-hoursUSD 170.25-0.08%2026-11-20 19:56 ET
Revenue FY 2026 · updated 2026-11-20 15:59 ETSource ↗

Financial history

Full market history
USD 0$0USD 50$12.5 BUSD 100$25.0 BUSD 150$37.5 BUSD 200$50.0 B2025-122026-012026-022026-032026-042026-052026-062026-072026-082026-092026-102026-11
MonthCloseMarket capChange
  • 2026-11USD 170.38$48.8 B-1.5%
  • 2026-10USD 172.97$48.8 B+0.4%
  • 2026-09USD 172.31$49.3 B+12.2%
  • 2026-08USD 153.56$44 B+11.0%
  • 2026-07USD 138.37$39.6 B+4.2%
  • 2026-06USD 132.83$38 B-2.0%
  • 2026-05USD 135.53$38.8 B+17.3%
  • 2026-04USD 115.55$33.1 B+1.4%
  • 2026-03USD 113.98$32.6 B-6.1%
  • 2026-02USD 121.38$34.7 B-9.3%
  • 2026-01USD 133.85$38.3 B-1.6%
  • 2025-12USD 136.07$38.9 B—
Monthly closes · 2025-12 – 2026-11 · Full market history

Ownership & Control

Shareholding as of 2026-06-30
Controlling entity
Publicly held — no controlling shareholder disclosed
Company type
Brand & Manufacturer
Insiders
0.19%
Institutions
95.41%(1,659 holders)
Free float
95.59%

Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.

In the press

All coverage →5 latest headlines1
Headlines aggregated from public feeds. Sentiment tags are keyword-based, not editorial judgement.

Agilent Technologies, Inc. is a global leader in analytical and life sciences instrumentation headquartered in Santa Clara, California. Founded in 1999 as a spin-off of Hewlett-Packard, the company designs, manufactures, and services chromatography, mass spectrometry, spectroscopy, cell analysis, and molecular diagnostics systems. In fiscal year 2025 Agilent generated US$6,948 million in revenue with 6.7% year-over-year growth, employed approximately 18,100 people, and served more than 285,000 laboratories worldwide.

Corporate Snapshot

Agilent traces its roots to Hewlett-Packard's test and measurement and chemical analysis businesses. In 1999 HP split into HP (computing) and Agilent (measurement, chemical analysis, and medical), and Agilent subsequently divested its semiconductor business as Avago (now Broadcom) in 2005 and its electronic measurement division as Keysight Technologies in 2014. Today the company operates three principal businesses: Diagnostics and Genomics Group, Life Sciences and Applied Markets Group, and Agilent CrossLab, which together cover the full analytical workflow from discovery research through applied analysis to clinical diagnostics.

The company's product portfolio is anchored by best-in-class liquid chromatography (LC), gas chromatography (GC), and mass spectrometry (MS) platforms — including the 6495 triple quadrupole LC/MS and 6545 Q-TOF systems — used extensively in pharmaceutical development, food safety, environmental testing, and clinical research. Agilent also supplies cell analysis solutions such as flow cytometry and real-time PCR, and materials science tools including FTIR, UV-Vis, and atomic spectroscopy systems. Its CrossLab services business provides instrument repair, calibration, and laboratory consulting, generating high-margin recurring revenue.

Key Strengths

Agilent's principal strength is its installed base and laboratory franchise. With analytical equipment running in over 285,000 research and industrial laboratories globally, the company enjoys a durable recurring revenue stream from consumables, columns, reagents, and service contracts that is more resilient than pure instrument sales. The 2026 acquisition of Biocare Medical for US$950 million added more than 300 specialized immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) antibody assays and instruments, significantly strengthening Agilent's position in oncology and pathology diagnostics — one of the fastest-growing segments in clinical testing.

Financially, Agilent has demonstrated strong recovery momentum. FY2025 revenue grew 6.7% to US$6,948 million, with fourth-quarter core growth accelerating to 7.2%, signaling a rebound from the 2023-2024 biopharma capex downturn. The company maintains a self-manufacturing model with production and R&D facilities across the United States, Europe, and Asia, providing supply-chain control and localization advantages. Its diagnostics portfolio, including the Agilent Dako pathology franchise and SureFISH probes, positions the company as a critical supplier to the global precision medicine ecosystem.

Challenges & Outlook

Agilent's main challenges are macro-cyclical exposure and intensifying competition. The biopharmaceutical capital equipment market remains sensitive to interest rates, tariff policy, and China trade tensions, which slowed orders in early 2025 and created volatility in reported revenue due to currency fluctuations. In China, Agilent's second-largest market, domestic instrument manufacturers are increasingly competitive in mid-range chromatography and spectroscopy, pressuring pricing and market share.

Looking forward, Agilent expects continued mid-single-digit to low-double-digit growth driven by the Biocare Medical integration, expansion in proteomics and spatial biology, and the secular growth of biopharma discovery and clinical diagnostics. Management has guided for improving margins as the instrument cycle recovers, and the company remains committed to returning capital through buybacks and dividends. With its deep laboratory installed base, expanding diagnostics franchise, and disciplined capital allocation, Agilent is well positioned to maintain its status among the world's leading analytical instrumentation companies through 2026 and beyond.

VerityRank Score of 89/100

Quick Facts

Headquarters

Santa Clara, California, United States

Founded

1999

Employees

~18,100

Revenue

US$7 B (FY2025)

Market cap

$48.8 B

Factories

Manufacturing and R&D facilities across the US, Europe, Asia and emerging markets

Presence

Analytical instruments deployed in over 285,000 laboratories worldwide

Listing

NYSE: A
Categories
Instruments & MetersIn-Vitro Diagnostics Equipment IndustryInstruments & Meters CompaniesInstruments & Meters ManufacturersLaboratory Equipment IndustryMedical Diagnostic Equipment IndustryScientific Analytical Instruments IndustryScientific Lab Instruments BrandsEnvironmental Monitoring Equipment BrandsScientific Lab Instruments Manufacturers

10 categories · scroll for more

Related

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website NYSE: A , Agilent Investor Financial Summary
Agilent Completes Biocare Medical Acquisition
Agilent Q4 FY2025 Results
Agilent Technologies – Wikipedia